Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Nanobodies that neutralize
Monoclonal antibodies that bind to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show therapeutic promise but must be produced in mammalian cells and need to be delivered intravenously. By contrast, single-domain antibodies called nanobodies can be produced in bacteria or yeast, and their stability may enable aerosol delivery. Two papers now report nanobodies that bind tightly to spike and efficiently neutralize SARS-CoV-2 in cells. Schoof et al. screened a yeast surface display of synthetic nanobodies and Xiang et al. screened anti-spike nanobodies produced by a llama. Both groups identified highly potent nanobodies that lock the spike protein in an inactive conformation. Multivalent constructs of selected nanobodies achieved even more potent neutralization.
Science
, this issue p.
Top-30
Citations by journals
2
4
6
8
10
12
|
|
Frontiers in Immunology
12 publications, 4.03%
|
|
International Journal of Molecular Sciences
7 publications, 2.35%
|
|
Nature Communications
7 publications, 2.35%
|
|
International Journal of Biological Macromolecules
7 publications, 2.35%
|
|
Viruses
6 publications, 2.01%
|
|
Journal of Biological Chemistry
6 publications, 2.01%
|
|
iScience
5 publications, 1.68%
|
|
Proceedings of the National Academy of Sciences of the United States of America
5 publications, 1.68%
|
|
Vaccines
4 publications, 1.34%
|
|
Scientific Reports
4 publications, 1.34%
|
|
Journal of Virology
4 publications, 1.34%
|
|
Communications Biology
3 publications, 1.01%
|
|
Structure
3 publications, 1.01%
|
|
Analytical Chemistry
3 publications, 1.01%
|
|
Science advances
3 publications, 1.01%
|
|
EMBO Reports
3 publications, 1.01%
|
|
eLife
3 publications, 1.01%
|
|
Virology
3 publications, 1.01%
|
|
International Journal of Nanomedicine
2 publications, 0.67%
|
|
Frontiers in Molecular Biosciences
2 publications, 0.67%
|
|
Frontiers in Drug Discovery
2 publications, 0.67%
|
|
Applied Microbiology and Biotechnology
2 publications, 0.67%
|
|
Nature Nanotechnology
2 publications, 0.67%
|
|
Cell
2 publications, 0.67%
|
|
Current Opinion in Virology
2 publications, 0.67%
|
|
Cell Reports
2 publications, 0.67%
|
|
Acta Pharmaceutica Sinica B
2 publications, 0.67%
|
|
Advanced Drug Delivery Reviews
2 publications, 0.67%
|
|
Biomedicine and Pharmacotherapy
2 publications, 0.67%
|
|
2
4
6
8
10
12
|
Citations by publishers
10
20
30
40
50
60
70
|
|
Elsevier
61 publications, 20.47%
|
|
Cold Spring Harbor Laboratory
55 publications, 18.46%
|
|
Springer Nature
40 publications, 13.42%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
25 publications, 8.39%
|
|
Frontiers Media S.A.
19 publications, 6.38%
|
|
Wiley
17 publications, 5.7%
|
|
American Chemical Society (ACS)
16 publications, 5.37%
|
|
American Society for Microbiology
7 publications, 2.35%
|
|
American Society for Biochemistry and Molecular Biology
6 publications, 2.01%
|
|
Royal Society of Chemistry (RSC)
5 publications, 1.68%
|
|
American Association for the Advancement of Science (AAAS)
5 publications, 1.68%
|
|
Proceedings of the National Academy of Sciences (PNAS)
5 publications, 1.68%
|
|
Oxford University Press
4 publications, 1.34%
|
|
Taylor & Francis
4 publications, 1.34%
|
|
EMBO press
4 publications, 1.34%
|
|
eLife Sciences Publications
3 publications, 1.01%
|
|
Dove Medical Press
2 publications, 0.67%
|
|
Public Library of Science (PLoS)
2 publications, 0.67%
|
|
The Chemical Society of Japan
1 publication, 0.34%
|
|
Akademiai Kiado
1 publication, 0.34%
|
|
Microbiology Society
1 publication, 0.34%
|
|
NEJM Group
1 publication, 0.34%
|
|
Portland Press
1 publication, 0.34%
|
|
Cambridge University Press
1 publication, 0.34%
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.34%
|
|
Rockefeller University Press
1 publication, 0.34%
|
|
American Institute of Mathematical Sciences (AIMS)
1 publication, 0.34%
|
|
Hindawi Limited
1 publication, 0.34%
|
|
Annual Reviews
1 publication, 0.34%
|
|
10
20
30
40
50
60
70
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.